The examination of the extracellular environment of NM23 and the molecule target therapy in malignant lymphoma
| Project/Area Number |
21591218
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
NIITSU Nozomi 埼玉医科大学, 医学部, 教授 (20256697)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 癌 / 蛋白質 |
|---|
| Research Abstract |
We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab-era. The subjects were DLBCL patients who underwent chemotherapy and in whom markers could be analyzed. Among DLBCL patients who underwent chemotherapy, BCL2-positivity, MUM1-positivity, non-GCB, and nm23-H1-positivity were associated with significantly shorter overall survival and progression-free survival. We demonstrated that among patients with DLBCL who underwent chemotherapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.
|
Report
(4 results)
Research Products
(32 results)
